Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1- oxoisoindolin-2-yl)piperidine-2,6-dione, methods of making these polymorphic forms, and compositions comprising these polymorphic forms. These polymorphic forms are useful in the treatment of various diseases, including, for example, breast cancer.
1. Crystalline (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound A)
characterized by an X-ray powder diffraction pattern having peaks at 4.1 °2θ±0.2°2θ, 13.9°2θ±0.2°2θ, 16.4°2θ±0.2°2θ, and 17.9°2θ±0.2°2θ using Cu Kα radiation at an x-ray wavelength of 1.5406 Å.
2. A pharmaceutical composition comprising the crystalline Compound A of claim 1 , and a pharmaceutically acceptable carrier.
3. The crystalline Compound A of claim 1 , wherein Compound A is substantially anhydrous.
4. The crystalline Compound A of claim 1 , wherein Compound A is substantially unsolvated.
5. The crystalline Compound A of claim 1 , wherein Compound A is substantially anhydrous and unsolvated.
6. The crystalline Compound A of claim 1 , wherein Compound A is about 99% pure.